Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 2321Neoplasms 1688Prostatic Neoplasms 1187Lung Neoplasms 914Colorectal Neoplasms 875Carcinoma, Non-Small-Cell Lung 849Leukemia, Myeloid, Acute 585Pancreatic Neoplasms 573Multiple Myeloma 545Carcinoma, Hepatocellular 515Brain Neoplasms 513Neoplasm Metastasis 462Head and Neck Neoplasms 459Melanoma 414Ovarian Neoplasms 409Glioblastoma 399Precursor Cell Lymphoblastic Leukemia-Lymphoma 388Stomach Neoplasms 371Uterine Cervical Neoplasms 359Squamous Cell Carcinoma of Head and Neck 356Rectal Neoplasms 335Recurrence 334Hematologic Neoplasms 327Sarcoma 324Lymphoma 314Colonic Neoplasms 314Triple Negative Breast Neoplasms 285Urinary Bladder Neoplasms 283Glioma 278Carcinoma, Renal Cell 278

Interventions

mirdametinib 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Primary Malignant Peripheral Nerve Sheath Tumors × 1 year × Clear all
NCT06693284 2026-05-29

A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]

University of Minnesota

Phase EARLY_PHASE1 Recruiting
8 enrolled

Primary Malignant Peripheral Nerve Sheath Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡